(Q54484718)

30 May 2018

title

Development of a transgenic mouse model immune tolerant for human interferon Beta. (English)

1 reference

30 May 2018

2

Wim Jiskoot

1 reference

30 May 2018

author name string

Suzanne Hermeling

1

1 reference

30 May 2018

Daan Crommelin

3

1 reference

30 May 2018

Claus Bornaes

4

1 reference

30 May 2018

Huub Schellekens

5

1 reference

30 May 2018

publication date

8 June 2005

1 reference

30 May 2018

published in

Pharmaceutical Research

1 reference

30 May 2018

volume

22

1 reference

30 May 2018

issue

6

1 reference

30 May 2018

page(s)

847-851

1 reference

30 May 2018

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-005-4578-Z

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-005-4578-Z

Development of antibodies to interferon beta in patients: technical and biological aspects

21 January 2018

1 reference

12 December 2020

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

1 reference

12 December 2020

Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis

1 reference

12 December 2020

Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo

1 reference

12 December 2020

Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

1 reference

12 December 2020

Immunogenicity of interferon beta: differences among products

1 reference

12 December 2020

The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model

1 reference

12 December 2020

Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice

1 reference

12 December 2020

Production of interferon-beta upon induction with polyinosinic acid:polycytidylic acid during the cell cycle of human fibroblasts

1 reference

12 December 2020

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

1 reference

12 December 2020

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

12 December 2020

Structure-immunogenicity relationships of therapeutic proteins

1 reference

12 December 2020

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

1 reference

12 December 2020

Transgenic mice as probes into complex systems

1 reference

12 December 2020

Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta

1 reference

12 December 2020

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b

1 reference

12 December 2020

Site-specific mutagenesis of the human fibroblast interferon gene

1 reference

12 December 2020

Interferon induction in piglets with polyinosinic:polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose

1 reference

12 December 2020

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

12 December 2020

10.1007/S11095-005-4578-Z

Identifiers

DOI

1 reference

30 May 2018

1 reference

30 May 2018